Superior Industries International (SUP) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Dan Lee - Senior VP & CFOMajdi Abulaban - President and CEO Operator Thank you for standing by. My name is Argy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Superior Industries First Quarter twenty twenty five Earnings Call. We are joined this morning by Madji Abulaban, President and CEO Dan Lee, Senior Vice President and CFO. All lines have been ...

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue of €311 million, representing a 17% year-over-year increase [8][24] - Adjusted EBITDA increased by 25% year-over-year to €59 million, with adjusted EBITDA margins expanding by 20 basis points to 19% [27][30] - Free cash flow generated during the quarter was €32 million, compared to breakeven cash flow in the same period a year ago, with a free cash flow conversion rate of 54% [31][32] Business Line Data and Key Metrics Changes - Technology and solutions revenue reached €250 million, growing 14% year-over-year, driven by a 13% increase in betting and gaming content [26] - Sports content, technology, and services revenue increased by 33% year-over-year to €61 million, led by a 36% growth in marketing and media services [26] - Managed betting services grew by 16% year-over-year, reflecting increased turnover and higher trading margins [26] Market Data and Key Metrics Changes - U.S. revenue grew by 31% and now represents 28% of total company revenues, indicating strong growth in the U.S. market [10][27] - The company is capitalizing on the expanding global sports betting market, which is expected to grow at a CAGR of 11% through 2027 [8][9] - Revenue from the rest of the world grew by 12% year-over-year, demonstrating broad-based growth across geographies [26] Company Strategy and Development Direction - The growth strategy is driven by four key pillars: global market expansion, increasing take rates, unlocking adjacent market opportunities, and driving innovation through technology and AI [8] - The company is focused on enhancing its product offerings, including the introduction of next-generation products to drive fan engagement [11][14] - The pending acquisition of IMG Arena's sports rights portfolio is expected to enhance growth strategy and strengthen premium content offerings [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to weather uncertainties, supported by approximately €2 billion of contractual revenue commitments locked in over the next two years [21] - The company anticipates continued strong revenue and EBITDA growth, with guidance for at least €1.273 billion in revenue and €281 million in adjusted EBITDA for 2025 [33][34] - Management noted that the U.S. market is still in an education phase regarding sports betting, but they expect adaptation to international trends [71][75] Other Important Information - The company completed a secondary offering, purchasing €65 million worth of shares under its existing share repurchase program, bringing total repurchases to €86 million [19][32] - The company is well-positioned to invest in long-term growth potential while returning capital to shareholders [32] Q&A Session Summary Question: What drove the U.S. growth of 31% in Q1? - Management attributed the growth to executing a well-defined strategy, leveraging a large portfolio of sports content, and strong monetization of products [39] Question: Is there any softness in the industry or player demographics? - Management indicated that the U.S. market is growing rapidly, with a significant portion of revenue coming from betting-related activities [40] Question: What are the expectations for the IMG acquisition? - Management confirmed that expectations for EBITDA accretion remain unchanged, with the deal expected to close by the end of Q3 or early Q4 [47][48] Question: What is the roadmap for computer vision data capture? - Management stated that while full automation is not feasible for all sports, they aim to cover about 90% of events, enhancing product offerings with more data points [64] Question: What are the biggest variables that could push revenue above the 15% CAGR? - Management highlighted market expansion, new product opportunities, and growth in adjacent markets as key factors that could drive higher revenue growth [92][94] Question: How durable is the growth in marketing and media services? - Management expressed confidence in the sustainability of growth, driven by better returns for clients and increased spending on marketing campaigns [96][99]

Advantage Solutions (ADV) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Ruben Mella - VP - IRDave Peacock - Chief Executive OfficerChris Growe - CFOJoseph Vafi - Managing Director, Equity ResearchFaiza Alwy - Managing Director, US Company Research Conference Call Participants William Reuter - Analyst Operator Greetings, and welcome to the Advantage Solutions First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. After the speakers' rem ...

Financial Data and Key Metrics Changes - Consolidated revenues for the third quarter reached $408 million, an 8% increase compared to the previous year [5][24] - Consolidated EBITDA totaled $38 million, maintaining healthy margins despite a shift in business mix [6][24] - The trailing twelve-month revenue to customer acquisition cost (CAC) ratio improved to 5.8x from 4.2x a year ago, indicating enhanced marketing efficiency [10][11] Business Line Data and Key Metrics Changes - Senior segment revenues totaled $169 million, with adjusted EBITDA of $46 million, resulting in a 27% EBITDA margin despite a 26% reduction in agent headcount [25][26] - Healthcare Services revenue grew 53% year-over-year to $190 million, with adjusted EBITDA of $6 million [29] - Life Insurance revenues increased by 13% to $46 million, with adjusted EBITDA more than doubling to $6 million, resulting in a 14% EBITDA margin [31] Market Data and Key Metrics Changes - The SelectRx business saw membership grow by 41% year-over-year, reaching 106,000 members [5][29] - The Medicare Advantage environment was characterized by a strong close rate despite a smaller agent force, with policies totaling 168,000, down less than 10% [12][26] Company Strategy and Development Direction - The company aims to enhance profitability in the Healthcare Services segment by refining membership parameters and focusing on efficiency [18][55] - Plans to increase agent hiring are underway to capitalize on market improvements, particularly in the Medicare Advantage space [42][43] - The opening of a new facility in Kansas is expected to drive long-term operational efficiency and margin expansion, although it may initially drag profitability [62] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the final rate notice for Medicare Advantage, which is expected to improve carrier reimbursement rates and market conditions [60] - The company anticipates potential headwinds in the fourth quarter due to new beneficiary eligibility parameters and the ramp-up of the Kansas facility [32][62] - Overall, management remains confident in the business model's ability to generate operating leverage and shareholder value [66] Other Important Information - The company is facing a Department of Justice complaint related to the Medicare Advantage system but plans to mount a vigorous defense [21][22] - Significant progress has been made on the capital structure, including a $100 million securitization and a $350 million strategic investment [34][35] Q&A Session Summary Question: Can you walk through the separation of growth in Medicare Advantage and SelectRx? - Management noted that while there was a 26% reduction in agent count, the close rates were strong due to tenured agents, which helped drive efficiency and attach rates to SelectRx [37][39] Question: What are the plans for agent growth in the upcoming season? - Hiring is currently underway, with expectations to discuss more in the upcoming guidance [42][43] Question: Can you provide insights on the receivable securitization? - Management indicated that securitization is a potential path for capital structure optimization, with several options being explored [44][45] Question: How should investors think about MA LTV moving forward? - A decline in MA LTV is expected in the fourth quarter due to the shift in commission structure, with further details to be shared in the next earnings call [49][51] Question: What benefits are expected from the new Kansas facility? - The facility is anticipated to improve operating efficiency and customer experience, although there will be a short-term drag on profitability [61][62]

Agenus (AGEN) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Zack Armen - Head of IR & Corporate DevelopmentDr. Garo Armen - Chairman & CEORichard Goldberg - Chief Development OfficerChristine Klaskin - Vice President of Finance, Principal Financial Officer & Principal Accounting OfficerSteven O’Day - Chief Medical OfficerJennifer Buell - Chairman & Executive CouncilMayank Mamtani - Senior Managing Director & Group Head of HealthcareMatt Phipps - Group Head - Biotechnology Conference Ca ...

Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $62.5 million, up 24% from $50.3 million in Q1 2024 [7][10] - Net product sales of Lupkinus were $60 million, a 25% increase from $48.1 million in the same period of 2024 [7][8] - Cash flow generated from operations was $1.3 million compared to a negative $18.6 million in Q1 2024; excluding restructuring payments, cash flow was $12.4 million [8][10] - The company had cash, cash equivalents, restricted cash, and investments of $312.9 million as of March 31, 2025, down from $358.5 million at the end of 2024 [9][10] - Net income was $23.3 million or $0.17 per share, compared to a net loss of $10.7 million or $0.07 per share in Q1 2024 [12] Business Line Data and Key Metrics Changes - The increase in net product sales of Lupkinus was primarily due to a rise in the number of cartons sold to specialty pharmacies and greater penetration in the lupus nephritis market [8][9] - Cost of revenue for Q1 2025 was $8.6 million, up from $7.8 million in Q1 2024, while gross margin improved to 86% from 85% [11][12] - Total operating expenses decreased to $40.6 million from $63.6 million in the same period of 2024, attributed to lower personnel expenses and reduced R&D costs [11][12] Market Data and Key Metrics Changes - The company is focused on educating rheumatologists about the benefits of initiating Lupkinus earlier in treatment, following updated guidelines from the American College of Rheumatology [9] - The company anticipates continued growth in the lupus nephritis market, supported by recent guideline updates that favor earlier diagnosis and treatment [26][52] Company Strategy and Development Direction - The company is maintaining a focus on commercial execution and operational efficiency, with a strong emphasis on the growth of Lupkinus [6][9] - The company reiterated its total revenue guidance for 2025 in the range of $250 million to $260 million and net product sales guidance of $240 million to $250 million [9][10] - The company is on track to report initial results from the Phase 1 study of AUR-200, a dual BAP inhibitor, later in the quarter [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Lupkinus, citing improvements in patient adds and rheumatology prescribing [17][18] - The company is closely monitoring potential impacts from government policies and tariffs, with minimal expected impact on costs due to existing stockpiles in the U.S. [31][32] - Management emphasized the importance of maintaining a competitive profile against new entrants in the lupus nephritis market [52][53] Other Important Information - The company has repurchased $5.8 million of its common shares in Q1 2025, part of a broader share repurchase program [9][10] - The company is actively defending its patents against ANDA filers and is committed to maintaining its revenue stream from Lupkinus [26][56] Q&A Session Summary Question: Can you discuss the quarterly cadence for Lupkinus sales and what is driving current sales? - Management indicated that sales are driven by a combination of new patient adds and persistency, with historical patterns suggesting a rise in sales in the latter half of the year [15][17] Question: What are the expectations for the second quarter compared to the first? - Management noted that Q1 is not typically the lowest quarter, with historical trends indicating a soft summer followed by a rise in Q4 [23][24] Question: Can you elaborate on the ANDA filers challenging the dosing protocol patent? - Management confirmed that they are vigorously defending their patents and that the process includes a 30-month stay for the filers [26] Question: What is the company's exposure to potential new federal government policies? - Management stated that they are monitoring the situation closely, with minimal expected impact on costs due to existing stockpiles in the U.S. [29][31] Question: What endpoints are anticipated to differentiate AUR-200 from other inhibitors? - Management indicated that the Phase 1 results will provide critical pharmacokinetic and pharmacodynamic data, which will help assess AUR-200's competitive profile [59]

Financial Data and Key Metrics Changes - SelectQuote reported consolidated revenues of $408 million for Q3 2025, an 8% increase compared to the previous year [4][21] - Consolidated EBITDA for the quarter was $38 million, reflecting a margin of 9% despite a mix shift towards lower-margin Healthcare Services [5][21] - The trailing twelve-month revenue to customer acquisition cost (CAC) ratio improved to 5.8x from 4.2x a year ago, indicating enhanced marketing efficiency [9][10] Business Line Data and Key Metrics Changes - The Senior segment generated $169 million in revenue with an adjusted EBITDA of $46 million, achieving a margin of 27% despite a 26% reduction in agent headcount [22][24] - Healthcare Services revenue grew 53% year-over-year to $190 million, with adjusted EBITDA of $6 million [27] - Life Insurance revenues increased by 13% to $46 million, with adjusted EBITDA more than doubling to $6 million, resulting in a margin of 14% [29] Market Data and Key Metrics Changes - SelectQuote's SelectRx business saw membership grow to 106,000, a 41% increase year-over-year, contributing to significant revenue growth [4][27] - The company noted a favorable final rate notice for the 2026 plan year, which is expected to alleviate pressures in the Medicare Advantage market [7][58] Company Strategy and Development Direction - The company aims to enhance profitability in its Healthcare Services segment by refining membership parameters and focusing on efficiency [15][51] - SelectQuote plans to leverage its scale and improve margin consistency, even if it results in slower membership growth in the near term [16][51] - The company is committed to maintaining high integrity and compliance in the Medicare Advantage industry amid ongoing legal challenges [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the Medicare Advantage landscape, citing improved agent efficiency and customer attachment rates [36][38] - The company anticipates potential headwinds in Q4 due to new beneficiary eligibility parameters and the ramp-up of its Kansas distribution facility [30][62] - Management remains optimistic about the long-term growth prospects of the Healthcare Services segment, despite short-term profitability challenges [16][62] Other Important Information - SelectQuote has made significant progress on its capital structure, including a $100 million securitization and a $350 million strategic investment [31][32] - The company ended the quarter with an operating cash flow of $71 million and a cash balance of $86 million [32][33] Q&A Session Summary Question: Can you walk through the separation of growth in Medicare Advantage and SelectRx? - Management noted that while there was a decline in Medicare Advantage volume due to a smaller agent count, the efficiency of tenured agents helped drive strong performance in SelectRx [35][36] Question: What are the plans for agent growth in the upcoming season? - Management indicated that hiring is underway and they feel positive about the early stages of recruitment for the next season [40][42] Question: Can you discuss the impact of receivable securitization? - Management confirmed that they are exploring additional securitization options and have made progress on their capital structure [43][45] Question: How should investors think about MA LTV moving forward? - Management expects MA LTV to be down year-over-year in Q4 due to the shift in commission structure but will provide more details in the next earnings call [48] Question: What are the expected benefits from the new Kansas facility? - Management anticipates long-term benefits in operating efficiency and customer experience, although there will be a short-term drag on profitability [61][62]

Financial Data and Key Metrics Changes - The company's first quarter revenues were $696 million, down 5% year-over-year, and adjusted EBITDA was $58 million, down 18% year-over-year [4][5][15] - The decline in adjusted EBITDA was primarily due to intentional client exits and transformation-related investments [5][15] Business Line Data and Key Metrics Changes - In Branded Services, revenues were $257 million and adjusted EBITDA was $28 million, down 9% year-over-year [18] - Experiential Services generated $221 million in revenues and $12 million in adjusted EBITDA, down 12% year-over-year [19] - Retailer Services had revenues of $218 million and adjusted EBITDA of $18 million, down 3% and 7% year-over-year, respectively [19] Market Data and Key Metrics Changes - Consumer confidence declined, leading to lower consumer purchases and reevaluation of spending by clients [5][6] - Retailers experienced destocking trends, impacting overall order volumes [50][53] Company Strategy and Development Direction - The company is focused on modernizing its tech infrastructure and enhancing analytics capabilities to drive efficiency [11][12] - A task force has been mobilized to improve labor utilization and address staffing challenges [13][14] - The company is committed to being a cost-leading solutions partner to CPGs and retailers despite a softer growth environment [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging labor market affecting event staffing and project execution [7][10] - Despite near-term challenges, the company remains optimistic about future performance and has a robust new business pipeline [6][7] - The revenue and adjusted EBITDA outlook has been lowered to flat to down low single digits due to macroeconomic factors [15][16] Other Important Information - The company ended the quarter with $121 million in cash and a net leverage ratio of approximately 4.4x adjusted EBITDA [20][26] - The ERP implementation is expected to yield greater cash flow benefits as systems are better utilized [25][26] Q&A Session Summary Question: Any notable changes in the macro environment? - Management noted improvements in hiring rates and smoother staffing challenges in Q2 compared to Q1 [32][33] Question: Have labor costs increased due to staffing issues? - Management indicated that labor cost inflation is in line with the macro market, and staffing issues were more related to talent acquisition strategies [39][40] Question: What is the impact of staffing shortages on EBITDA? - The majority of the decline in EBITDA was attributed to staffing shortages [68] Question: Is destocking continuing into Q2? - Destocking improved as Q1 progressed, but data for April was not yet available to confirm if it had completely stopped [70] Question: Breakdown of consumer products versus food companies? - Approximately 70% of the portfolio is in food, with strong presence in personal care and household goods [73]

Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $62.5 million, up 24% from $50.3 million in Q1 2024 [5] - Net product sales of Lupkinus were $60 million, up 25% from $48.1 million in the same period of 2024 [5] - Cash flow generated from operations was $1.3 million compared to a negative $18.6 million in Q1 2024; excluding restructuring payments, cash flow was $12.4 million [5][6] - Net income was $23.3 million or $0.17 per share, compared to a net loss of $10.7 million or $0.07 per share in Q1 2024 [10] Business Line Data and Key Metrics Changes - The increase in net product sales of Lupkinus was primarily due to a rise in the number of cartons sold to specialty pharmacies and greater penetration in lupus nephritis treatment [5] - Cost of revenue for Q1 2025 was $8.6 million, up from $7.8 million in Q1 2024, while gross margin improved to 86% from 85% [9] Market Data and Key Metrics Changes - The company has seen improvements in rheumatology prescribing, indicating early diagnosis and treatment trends [16] - The American College of Rheumatology updated guidelines recommending the incorporation of drugs like Lupkinus into first-line therapy, which is expected to drive further growth [6] Company Strategy and Development Direction - The company is focused on commercial execution and operational efficiency, aiming for continued growth in Lupkinus sales and advancing the AUR 200 clinical program [6][11] - Total revenue guidance for 2025 is maintained in the range of $250 million to $260 million, with net product sales guidance of $240 million to $250 million [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for Lupkinus, citing historical performance patterns and ongoing improvements in patient treatment initiation [15][16] - The company is closely monitoring potential impacts from new federal government policies and tariffs, with minimal expected impact on operations due to existing stockpiles in the U.S. [29][30] Other Important Information - The company repurchased $5.8 million of its common shares in Q1 2025, part of a broader share repurchase program [6][9] - The company is on track to report initial results from the Phase 1 study of AUR 200 later in the quarter [7] Q&A Session Summary Question: Can you discuss the quarterly cadence for Lupkinus sales and what is driving sales? - Management indicated that sales are driven by a combination of new patient additions and persistency, with historical patterns suggesting a rise in sales in the latter half of the year [15] Question: What are the expectations for the second quarter compared to the first? - Management clarified that Q1 is not typically the lowest quarter, with historical trends indicating a soft summer followed by a rise in Q4 [21][22] Question: Can you elaborate on the ANDA filers challenging the dosing protocol patent? - The company is actively defending its patents and has filed infringement lawsuits against ANDA filers, with ongoing litigation expected [24] Question: What is the company's exposure to potential tariffs and government reimbursement policies? - The company has several years of product stockpiled in the U.S. and does not anticipate significant impact from tariffs on overall costs [29][30] Question: What endpoints are expected to differentiate AUR 200 from other inhibitors? - The Phase 1 results will provide insights into pharmacokinetics and pharmacodynamics, which will help assess AUR 200's competitive profile [60]

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue of €311 million, representing a 17% year-over-year increase [7][22] - Adjusted EBITDA increased by 25% year-over-year to €59 million, with adjusted EBITDA margins expanding by 20 basis points to 19% [25][28] - Free cash flow generated during the quarter was €32 million, compared to breakeven cash flow in the same period last year, with a free cash flow conversion rate of 54% [28][29] Business Line Data and Key Metrics Changes - Technology and solutions revenue reached €250 million, growing 14% year-over-year, driven by a 13% increase in betting and gaming content [23] - Sports content, technology, and services revenue increased by 33% year-over-year to €61 million, led by a 36% growth in marketing and media services [24] - Managed betting services grew by 16% year-over-year, supported by increased turnover and higher trading margins [23] Market Data and Key Metrics Changes - U.S. revenue grew by 31% and now represents 28% of total company revenues, reflecting strong growth in the domestic market [9][24] - Revenue from the rest of the world grew by 12% year-over-year [24] - The global sports betting market is expected to grow at a CAGR of 11% through 2027, with established markets like Europe continuing to perform well [7][8] Company Strategy and Development Direction - The growth strategy is driven by four key pillars: global market expansion, increasing take rates, unlocking adjacent market opportunities, and driving innovation through technology and AI [7][16] - The company is focused on expanding its product offerings and enhancing client relationships, with only 40% of clients currently using four or more products, indicating significant growth potential [10][22] - The pending acquisition of IMG Arena's sports rights portfolio is expected to enhance growth strategy and strengthen premium content offerings [16][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to weather uncertainties and highlighted the resilience of the global online sports betting market [19][18] - The company anticipates continued strong revenue and EBITDA growth, with guidance for at least €1.273 billion in revenue and €281 million in adjusted EBITDA for 2025 [31][32] - Management noted that the acquisition of IMG Arena is expected to be immediately accretive to adjusted EBITDA and cash margins [17][30] Other Important Information - The company completed a secondary offering, purchasing $65 million worth of shares under its existing $200 million share repurchase program, bringing total repurchases to $86 million [17][29] - The company has approximately $2 billion in contractual revenue commitments locked in over the next two years, providing strong visibility for future growth [19] Q&A Session Summary Question: What drove the outperformance in U.S. growth? - Management attributed the 31% growth in the U.S. to executing their strategy effectively, leveraging their extensive portfolio in major sports leagues [36][37] Question: Is there any softness in the industry or player demographics? - Management indicated that the U.S. market is still adapting, and while some sportsbooks are quicker to adopt in-game betting, the overall trend is positive [40][41] Question: What are the expectations for the IMG acquisition? - Management confirmed that expectations for EBITDA accretion remain unchanged, with the deal expected to close by the end of Q3 or beginning of Q4 [45][46] Question: What is the roadmap for computer vision data capture? - Management stated that they aim to cover about 90% of events with computer vision, which enhances product offerings and monetization opportunities [62][64] Question: What are the key variables that could push revenue growth above 15% CAGR? - Management highlighted market expansion, new product opportunities, and growth in adjacent markets as potential drivers for exceeding the 15% CAGR target [92][95]